Opdivo

Opdivo
Fvasconcellos (talk · contribs) · Public domain · source
Name	Opdivo
Type	Monoclonal antibody
Tradename	Opdivo
Generic name	Nivolumab
Routes	Intravenous
Legal status	Prescription only

Opdivo

Opdivo is a monoclonal antibody immune checkpoint inhibitor used in oncology. It was developed to target programmed death-1 pathways and has been studied across a range of malignancies, cancer centers, clinical consortia and regulatory agencies. Major oncology organizations, pharmaceutical companies, and research universities have published trials and guidelines related to its use.

Medical uses

Opdivo is indicated for multiple malignancies in guidelines from bodies such as National Comprehensive Cancer Network, European Society for Medical Oncology, and specialty societies in contexts including metastatic melanoma, non-small cell lung cancer, classical Hodgkin lymphoma, renal cell carcinoma, hepatocellular carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma, and microsatellite instability-high or mismatch repair-deficient solid tumors evaluated in consortia like American Society of Clinical Oncology and registries such as Surveillance, Epidemiology, and End Results Program. Clinical use often intersects with multidisciplinary teams at centers like Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and specialty networks including National Cancer Institute cooperative groups. Treatment decisions reference staging systems from organizations like AJCC and biomarker testing platforms developed by laboratories affiliated with Mayo Clinic and MD Anderson Cancer Center.

Mechanism of action

Opdivo binds to the programmed death-1 receptor, modulating interactions with ligands studied in structural biology programs at institutions such as Rockefeller University and reported in journals affiliated with publishers like Nature Publishing Group, Elsevier, and John Wiley & Sons. The blockade of PD-1/PD-L1 interactions alters tumor-immune microenvironment assessments developed by researchers at Harvard Medical School, Stanford University School of Medicine, and translational units at Cold Spring Harbor Laboratory. Mechanistic studies reference signaling pathways investigated in laboratories connected to Max Planck Society and German Cancer Research Center (DKFZ), and preclinical models from institutions like Salk Institute and Broad Institute.

Clinical trials and efficacy

Pivotal trials were conducted in multicenter collaborations including pharmaceutical partners such as Bristol Myers Squibb and academic networks like European Organisation for Research and Treatment of Cancer and cooperative groups including EORTC and Alliance for Clinical Trials in Oncology. Major phase III trials reported endpoints consistent with standards from International Conference on Harmonisation guidelines and were presented at meetings such as American Association for Cancer Research, European Society for Medical Oncology Congress, and American Society of Clinical Oncology Annual Meeting. Efficacy data have been compared with chemotherapeutic regimens from manufacturers like Pfizer, targeted agents from Roche, and combination strategies explored with agents from Merck & Co. and AstraZeneca. Long-term outcome analyses referenced cancer registries like SEER and survival metrics standardized by World Health Organization collaborations.

Dosage and administration

Administration protocols used in clinical practice align with infusion standards from hospital systems such as Cleveland Clinic and oncology pharmacy guidelines from organizations like American Society of Health-System Pharmacists. Dosage schemes were established in trials run by cooperative networks including SWOG and dosing modifications referenced prescribing information reviewed by regulatory bodies such as Food and Drug Administration and European Medicines Agency. Preparation and handling procedures reflect sterile compounding guidance from United States Pharmacopeia and infusion center workflows used at institutions including Johns Hopkins Hospital.

Adverse effects and safety

Safety profiles have been characterized in safety committees and pharmacovigilance programs involving agencies such as FDA and EMA and postmarketing surveillance coordinated with databases like VigiBase and EudraVigilance. Immune-related adverse events were described in consensus statements from societies including American Academy of Allergy, Asthma & Immunology and managed according to protocols developed by centers such as Moffitt Cancer Center and University of California, San Francisco Medical Center. Reported toxicities have been analyzed alongside safety data for other immunotherapies from companies like Amgen and compared to toxicity grading criteria from CTCAE maintained by NCI.

Regulatory approval and commercialization

Regulatory approvals were granted by authorities including Food and Drug Administration, European Medicines Agency, Japan Pharmaceuticals and Medical Devices Agency, and health technology assessment bodies like National Institute for Health and Care Excellence. Commercialization involved marketing and licensing arrangements between Bristol Myers Squibb and regional partners, distribution through pharmaceutical supply chains that include wholesalers like McKesson Corporation and hospital procurement managed by purchasing groups such as Premier, Inc.. Reimbursement decisions have engaged payers like Centers for Medicare & Medicaid Services and private insurers such as Aetna and UnitedHealthcare, with pricing and policy debates considered in forums like World Health Assembly and scholarship from economic units at London School of Economics.

Category:Monoclonal antibodies